Get the Stockscreener App
10.81
2.79%
-0.31
Fibrogen Inc stock is traded at $10.81, with a volume of 9,865.
It is down -2.79% in the last 24 hours and down -12.19% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$11.12
Open:
$11.06
24h Volume:
9,865
Relative Volume:
0.24
Market Cap:
$43.71M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.6894
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-3.05%
1M Performance:
-12.19%
6M Performance:
+32.84%
1Y Performance:
+44.71%
1-Day Range:
$10.81
$11.21
1-Week Range:
$10.59
$11.65
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
10.81 | 44.97M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
Technical signs of recovery in FibroGen Inc.Inflation Watch & Real-Time Chart Pattern Alerts - newser.com
What does recent volatility data suggest for FibroGen Inc.Breakout Watch & Verified High Yield Trade Plans - newser.com
Should you hold or exit FibroGen Inc. nowDividend Hike & Low Risk Investment Opportunities - newser.com
Forecasting FibroGen Inc. price range with options dataWeekly Profit Analysis & AI Based Trade Execution Alerts - newser.com
Is FibroGen Inc. reversing from oversold territoryQuarterly Growth Report & Fast Gain Swing Alerts - newser.com
Why FibroGen Inc. stock attracts global investorsJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Is FibroGen Inc. stock attractive for hedge fundsJuly 2025 Movers & Breakout Confirmation Trade Signals - newser.com
What to expect from FibroGen Inc. in the next 30 daysQuarterly Market Review & Momentum Based Trading Signals - newser.com
Can FibroGen Inc. (1FG0) stock reach $200 price targetWall Street Watch & Verified Technical Signals - newser.com
Chart based exit strategy for FibroGen Inc.July 2025 Closing Moves & Momentum Based Trading Signals - newser.com
Can FibroGen Inc. stock sustain institutional interestJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Can FibroGen Inc. stock outperform in 2025 bull market2025 Stock Rankings & Smart Money Movement Tracker - newser.com
How to integrate FibroGen Inc. into portfolio analysis toolsWeekly Trade Summary & AI Powered Buy and Sell Recommendations - newser.com
Building trade automation scripts for FibroGen Inc.July 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Is FibroGen Inc. (1FG0) stock expanding market penetrationEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
How to read the order book for FibroGen Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
What hedge fund activity signals for FibroGen Inc. stockGap Up & Free Expert Approved Momentum Trade Ideas - newser.com
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):